Targeted delivery of Rab26 siRNA with precisely tailored DNA prism for lung cancer therapy.

In this study, a GTPase Rab26 was explored as a new potential therapeutic target using precisely tailored DNA prism for targeted lung cancer therapy. Specifically, a DNA prism platform with tunable targeting and siRNA loading capability is designed and synthesized. The DNA prisms were decorated with two functional units: a Rab26 siRNA as the drug and MUC-1 aptamers as targeting moiety for non-small cell lung cancer. The number and position of both siRNA and MUC-1 aptamer can be readily tuned. Native polyacrylamide gel electrophoresis (PAGE) and dynamic light scattering technique (DLS) demonstrate that all nanoprisms with different functionalities are self-assembled with high yield. It is also found that the cellular uptake of DNA prims is proportional to the aptamer number on each nanoprism, and the as-prepared DNA nanoprism show excellent anti-cancer activities and targeting capability. Current study suggest that by careful design, self-assembled DNA nanostructures are highly promising, customizable, multifuncitonal nanoplatform for potential biomedical applications, such as personalized precision therapy in the near future. PMID: 30610755 [PubMed - as supplied by publisher]
Source: Chembiochem - Category: Biochemistry Authors: Tags: Chembiochem Source Type: research